according to the Globally Harmonized System



Furosemide Solid Formulation

Version **Revision Date:** SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

1. PRODUCT AND COMPANY IDENTIFICATION

Product name Furosemide Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address Briahnager - Off Pune Nagar Road

Wagholi - Pune - India 412 207

Telephone +1-908-740-4000

Emergency telephone number: +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Veterinary product Recommended use Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Specific target organ toxicity - : Category 1 (Kidney, Liver)

repeated exposure

GHS label elements

Hazard pictograms

Signal word

H372 Causes damage to organs (Kidney, Liver) through pro-Hazard statements

longed or repeated exposure.

Precautionary statements Prevention:

P260 Do not breathe dust.

P264 Wash hands thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

according to the Globally Harmonized System



Furosemide Solid Formulation

Date of last issue: 28.09.2024 **Revision Date:** Version SDS Number: 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Response:

P319 Get medical help if you feel unwell.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture Mixture

Components

Chemical name	CAS-No.	Concentration (%
		w/w)
Starch	9005-25-8	>= 50 - < 70
Furosemide	54-31-9	>= 10 - < 20
Cellulose	9004-34-6	>= 1 - < 5

4. FIRST AID MEASURES

General advice In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled, remove to fresh air. If inhaled

Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

> Get medical attention if irritation develops and persists. If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

If swallowed

Contact with dust can cause mechanical irritation or drying of

the skin. Dust contact with the eyes can lead to mechanical irritation.

Causes damage to organs through prolonged or repeated

exposure.

Protection of first-aiders First Aid responders should pay attention to self-protection,

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Nitrogen oxides (NOx)

Carbon oxides Sulphur oxides Chlorine compounds

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling

Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage

Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid

Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Starch	9005-25-8	TWA	10 mg/m3	ACGIH
Furosemide	54-31-9	TWA	200 μg/m3	Internal
		TWA	OEB 2 (>=100 - 1000 ug/m3)	Internal
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH

Engineering measures: Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type

Particulates type

Hand protection

Material : Chemical-resistant gloves

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : yellow

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : Not applicable

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of :

exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Method: Calculation method

Components:

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Furosemide:

Acute oral toxicity : LD50 (Rat): 2,600 mg/kg

LD50 (Dog): 2,000 mg/kg

LD50 (Rabbit): 800 mg/kg

Acute toxicity (other routes of :

administration)

LD0 (Humans): 6 - 29 mg/kg

Application Route: Intravenous

LD50 (Rat): 800 mg/kg

Application Route: Intravenous

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

according to the Globally Harmonized System



Furosemide Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 28.09.2024

 5.1
 14.04.2025
 658060-00017
 Date of first issue: 03.05.2016

Components:

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Furosemide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: positive

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro) Test system: mammalian liver cells

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: positive

Test Type: In vitro sister chromatid exchange assay in mam-

malian cells

Test system: Chinese hamster cells

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Chinese hamster Application Route: Ingestion

Result: negative

Cellulose:

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Furosemide:

Species : Rat
Application Route : Ingestion
Exposure time : 104 weeks

LOAEL : 16 mg/kg body weight

Result : equivocal

Species : Mouse
Application Route : Ingestion
Exposure time : 2 Years

LOAEL : 91 mg/kg body weight

Result : positive

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Furosemide:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

General Toxicity - Parent: NOAEL: 90 mg/kg body weight

Result: No effects on reproduction parameters

Test Type: One-generation reproduction toxicity study

Species: Mouse

Application Route: Ingestion

General Toxicity - Parent: NOAEL: 200 mg/kg body weight

Result: No effects on reproduction parameters

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

General Toxicity Maternal: LOAEL: 50 mg/kg body weight Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: No embryotoxic effects, No teratogenic effects

Test Type: Fertility/early embryonic development

Species: Mouse

Application Route: Ingestion

General Toxicity Maternal: LOAEL: 25 mg/kg body weight

Result: Maternal toxicity observed., Fetal effects

Test Type: Fertility/early embryonic development

Species: Rabbit

Application Route: Ingestion

General Toxicity Maternal: LOAEL: <= 12 mg/kg body weight Developmental Toxicity: LOAEL: 12.5 mg/kg body weight Result: Maternal toxicity observed., Reduced number of viable

fetuses

Test Type: Fertility/early embryonic development

Species: Rabbit

Application Route: Ingestion

General Toxicity Maternal: LOAEL: 15 mg/kg body weight Result: Maternal toxicity observed., No effects on foetal de-

velopment

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Causes damage to organs (Kidney, Liver) through prolonged or repeated exposure.

Components:

Furosemide:

Exposure routes : Ingestion Target Organs : Kidney

Assessment : Shown to produce significant health effects in animals at con-

centrations of 10 mg/kg bw or less.

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Repeated dose toxicity

Components:

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Furosemide:

Species: DogNOAEL: 4 mg/kgLOAEL: 8 mg/kgApplication Route: IngestionExposure time: 12 MonthsTarget Organs: Kidney

Symptoms : Blood disorders

Remarks : Significant toxicity observed in testing

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Furosemide:

Inhalation : Remarks: May be harmful if inhaled.

Skin contact : Remarks: May irritate skin.

Eye contact : Remarks: May cause eye irritation.

Ingestion : Symptoms: Kidney disorders, Headache, electrolyte imbal-

ance, dry mouth, hearing loss, Irregular cardiac activity, Gas-

trointestinal disturbance, hypotension

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Furosemide:

Toxicity to fish : LC50: 500 mg/l

Exposure time: 96 h

according to the Globally Harmonized System



Furosemide Solid Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 28.09.2024

 5.1
 14.04.2025
 658060-00017
 Date of first issue: 03.05.2016

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Bioaccumulative potential

Components:

Furosemide:

Partition coefficient: n-

octanol/water

log Pow: 2.03

Mobility in soil

No data available

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 14.04.2025

Further information

Sources of key data used to

compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substanc-

according to the Globally Harmonized System



Furosemide Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024 5.1 14.04.2025 658060-00017 Date of first issue: 03.05.2016

es; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN